| Literature DB >> 35996659 |
Wei Xu1, Changsheng Teng1, Guoqian Ding1, Ning Zhao1.
Abstract
Background: This study aimed to compare the risk of hypoparathyroidism between the transoral vestibular approach (TOVA) and the breast approach (BA) in patients undergoing total endoscopic thyroidectomy (TET) for papillary thyroid carcinoma (PTC).Entities:
Keywords: endoscopic; hypoparathyroidism; papillary thyroid carcinoma; parathyroid hormone; surgery; thyroidectomy
Year: 2022 PMID: 35996659 PMCID: PMC9391930 DOI: 10.2147/CMAR.S380024
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.602
Clinicopathologic Characteristics and Surgical Data According to Group
| Characteristic | BA (n=101) | TOVA(n=20) | |
|---|---|---|---|
| Clinical characteristics | |||
| Age (years) | 38.64±8.32 | 40.85±8.33 | 0.28 |
| Sex (female/male) | 101/0 | 20/0 | – |
| Pathologic characteristics | |||
| Tumor Size (mean, cm) | 0.81±0.62 | 0.87±0.55 | 0.70 |
| Tumor Location (L/R/I/W) | 7/12/0/1 | 40/45/4/12 | 0.48 |
| Multiple tumors (Y/N) | 20/81 | 2/18 | 0.30 |
| RLN invasion (Y/N) | 3/98 | 0/20 | 0.44 |
| Capsule invasion (Y/N) | 32/69 | 4/16 | 0.30 |
| Vascular invasion (Y/N) | 8/93 | 1/19 | 0.65 |
| Lymphatic metastasis (Y/N) | 48/53 | 9/11 | 0.84 |
| Disease in background thyroid | |||
| Nodular goiter (Y/N) | 20/81 | 4/16 | 0.98 |
| Hashimoto thyroiditis (Y/N) | 33/68 | 5/15 | 0.50 |
| Surgical procedures | |||
| Central lymph node dissection (U/B) | 35/66 | 5/15 | 0.40 |
| Lymph node dissection (n) | 7.82±5.34 | 9.40±4.56 | 0.22 |
| Parathyroid autotransplantation (Y/N) | 58/43 | 10/10 | 0.54 |
| IONM | 101/0 | 20/0 | – |
| IONM signal weaken (Y/N) | 10/91 | 2/18 | 0.99 |
| Negative margin (Y/N) | 101/0 | 20/0 | – |
| Capsular disruption (Y/N) | 0/101 | 0/20 | – |
Abbreviations: BA, breast approach; TOVA, transoral vestibular approach; L/R/I/W, left/right/isthmus/whole thyroid; Y/N, yes/no; U/B, unilateral/bilateral.
Hypoparathyroidism Incidence and Concentrations of Parathyroid Hormone and Calcium Over Time According to Group
| BA (n=101) | TOVA (n=20) | |||
|---|---|---|---|---|
| Hypoparathyroidism | Transient | 64/37 | 2/18 | <0.01 |
| Persistent | 7/94 | 1/19 | 0.75 | |
| PTH | ||||
| Preoperative | Mean | 43.03±15.44 | 41.85±17.38 | 0.76 |
| 2 days post-op | Mean | 11.75±11.84 | 27.38±12.13 | <0.01 |
| A/N | 64/37 | 2/18 | <0.01 | |
| 1 month post-op | Mean | 27.95±17.40 | 33.86±13.96 | 0.16 |
| A/N | 18/83 | 2/18 | 0.39 | |
| 6 month post-op | Mean | 30.46±15.35 | 34.69±16.48 | 0.27 |
| A/N | 7/94 | 1/19 | 0.75 | |
| 1 year post-op | Mean | 30.82±15.36 | 37.45±19.94 | 0.10 |
| A/N | 3/98 | 1/19 | 0.64 | |
| Calcium | ||||
| Preoperative | Mean | 2.34±0.07 | 2.36±0.08 | 0.34 |
| 2 days post-op | Mean | 2.06±0.16 | 2.09±0.10 | 0.33 |
| A/N | 68/33 | 7/11 | 0.01 | |
| 1 month post-op | Mean | 2.19±0.18 | 2.29±0.14 | 0.02 |
| A/N | 22/79 | 3/17 | 0.49 | |
| 6 month post-op | Mean | 2.22±0.14 | 2.29±0.15 | 0.05 |
| A/N | 14/87 | 2/18 | 0.64 | |
| 1 year post-op | Mean | 2.22±0.17 | 2.28±0.17 | 0.09 |
| A/N | 17/84 | 2/18 | 0.44 |
Abbreviations: BA, breast approach; TOVA, transoral vestibular approach; PTH, parathyroid hormone; post-op, postoperatively; A/N, abnormal/normal.
Univariate and Multivariate Analyses of Factors Associated with Transient and Persistent Hypoparathyroidism
| Characteristics | Transient Hypoparathyroidism (n=66) | Persistent Hypoparathyroidism (n=8) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||
| (Y/N) | P-value | HR (95% CI) | P-value | (Y/N) | P-value | HR (95% CI) | P-value | ||
| Age (years) | ≤55 | 64/53 | 0.85 | 0.80 | 8/0 | 0.59 | 0.99 | ||
| >55 | 2/2 | 0/4 | |||||||
| Different approaches | TOVA | 2/18 | <0.01 | 0.05 (0.01–0.23) | <0.01 | 1/19 | 0.75 | – | 0.94 |
| BA | 64/37 | 7/94 | |||||||
| Central lymph node dissection | Unilateral | 20/20 | 0.56 | 0.51 | 5/35 | 0.11 | 0.09 | ||
| Bilateral | 46/35 | 3/78 | |||||||
| Parathyroid autotransplantation | Y | 42/26 | 0.10 | 0.11 | 3/65 | 0.27 | 0.40 | ||
| N | 24/29 | 5/48 | |||||||
| Tumor size (cm) | >1 | 17/19 | 0.29 | 0.76 | 3/33 | 0.62 | 0.84 | ||
| ≤1 | 49/36 | 5/80 | |||||||
| Multiple tumors | Y | 13/9 | 0.64 | 0.93 | 3/19 | 0.14 | 0.12 | ||
| N | 53/46 | 5/94 | |||||||
| RLN invasion | Y | 1/2 | 0.46 | 0.42 | 0/3 | 0.64 | 0.99 | ||
| N | 65/53 | 8/110 | |||||||
| Capsule invasion | Y | 17/19 | 0.29 | 0.35 | 3/33 | 0.62 | 0.92 | ||
| N | 49/36 | 5/80 | |||||||
| Vascular invasion | Y | 5/4 | 0.95 | 0.91 | 0/9 | 0.41 | 0.99 | ||
| N | 61/51 | 8/104 | |||||||
| Lymphatic metastasis | Y | 27/30 | 0.14 | 0.13 | 3/54 | 0.57 | 0.79 | ||
| N | 39/25 | 5/59 | |||||||
| Hashimoto thyroiditis | Y | 21/17 | 0.92 | 0.76 | 4/34 | 0.24 | 0.25 | ||
| N | 45/38 | 4/79 | |||||||
| Nodular goiter | Y | 12/12 | 0.62 | 0.82 | 1/23 | 0.59 | 0.98 | ||
| N | 54/43 | 7/90 | |||||||
Abbreviations: Y/N, yes/no; HR, hazard ratio; CI, confidence interval; RLN, recurrent laryngeal nerve; TOVA, transoral vestibular approach; BA, breast approach.